Establishment Labs Holdings Inc

Establishment Labs raised its full-year revenue forecast to $269 million to $271 million after second-quarter revenue rose 31.7% year over year to $67.5 million. Adjusted EBITDA improved to positive $3.7 million from a loss of $8.5 million a year earlier. U.S. revenue surged 140.9% to $24.7 million, with more than 100,000 Motiva implants sold and over 2,000 accounts. The Minimally Invasive platform, which includes Mia and Preservé, generated $12.1 million in quarterly revenue, and Preservé exceeded surgeon-training expectations while commanding a significant pricing premium. Gross margin increased to 70.6%, cash reached $71.2 million, and management said no future equity raises are needed, with the company expecting to become free-cash-flow positive in the second half of 2026.

Establishment Labs has appointed Taylor Harris to its Board of Directors. Mr. Harris brings more than 25 years of experience in corporate finance, executive leadership and board governance across healthcare, medical technology and life sciences companies. He most recently served as Chief Executive Officer of Cutera, and previously was Chief Financial Officer of MyoKardia, where he helped guide the company through its acquisition by Bristol Myers Squibb in a transaction valued at $13.1 billion. He also served as CFO of Zeltiq Aesthetics through its acquisition by Allergan and as CFO of Thoratec Corporation through its acquisition by St. Jude Medical. Chairman Nick Lewin said Mr. Harris's deep expertise in the medical aesthetics industry and his track record of creating substantial value will be a tremendous asset as Establishment Labs becomes a leader in the global aesthetics market.